drugset / Trial / NCT00184548
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity. Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been merged.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | 100 ug/kg | Intravenous |